John Adams

Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis

Karin Przyklenk, Andrew L. Frelinger, Matthew D. Linden et al. · Journal of Thrombosis and Haemostasis · 2009 · 60 citations · Full text

Medicine, Cardiology, Pharmacology +17

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

Fernando Torres, Harrison W. Farber, Arsen Ristić et al. · European Respiratory Journal · 2019 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection

Tong Zhang, Zhuangjie Li, Huong Dang et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2011 · 43 citations

Medicine, Cardiology, Pharmacology +16

Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents

Joel Castro, Sonia Garcia‐Caraballo, Jessica Maddern et al. · Pain · 2021 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist

John Adams, Juan Ignacio Ramirez, Danny Ortuno et al. · European Journal of Pharmacology · 2007 · 26 citations

Medicine, Hematology, Pharmacology +11